Cargando…

Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results

BACKGROUND: This analysis assessed improvements in patients with radiographic axial spondyloarthritis (r-axSpA) treated with ixekizumab in the Assessment of Spondyloarthritis International Society (ASAS) treatment response domains and additional patient-reported outcomes at 1 year of treatment. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deodhar, Atul A., Mease, Philip J., Rahman, Proton, Navarro-Compán, Victoria, Strand, Vibeke, Hunter, Theresa, Bolce, Rebecca, Leon, Luis, Lauzon, Steve, Marzo-Ortega, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451150/ https://www.ncbi.nlm.nih.gov/pubmed/34538257 http://dx.doi.org/10.1186/s41927-021-00205-3

Ejemplares similares

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
por: Deodhar, Atul, et al.
Publicado: (2021)

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
por: Deodhar, Atul, et al.
Publicado: (2020)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
por: Maksymowych, Walter P, et al.
Publicado: (2022)

The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)

Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Publicado: (2020)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review
por: Mease, Philip, et al.
Publicado: (2022)

Coxitis in axial spondyloarthritis: the unmeasured, yet functionally most important, radiographic progression
por: Rocha, Francisco Airton Castro, et al.
Publicado: (2021)

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2022)

Patient Burden of Axial Spondyloarthritis
por: Strand, Vibeke, et al.
Publicado: (2017)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
por: Deodhar, Atul, et al.
Publicado: (2019)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
por: Deodhar, Atul, et al.
Publicado: (2023)

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
por: Deodhar, Atul, et al.
Publicado: (2019)

Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
por: Boel, Anne, et al.
Publicado: (2021)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States
por: Deodhar, Atul, et al.
Publicado: (2020)

Editorial: Radiographic progression in axial spondyloarthritis
por: Pimentel-Santos, F. M., et al.
Publicado: (2023)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain
por: Deodhar, Atul, et al.
Publicado: (2016)

Active Inflammatory and Chronic Structural Damages of Sacroiliac Joint in Patients With Radiographic Axial Spondyloarthritis and Non-Radiographic Axial Spondyloarthritis
por: Tu, Liudan, et al.
Publicado: (2021)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020)

Axial Spondyloarthritis in the Chiropractic Care Setting: A Systematic Literature Review
por: Deodhar, Atul, et al.
Publicado: (2022)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Spinal mobility in radiographic axial spondyloarthritis: criterion concurrent validity of classic and novel measurements
por: Snow, John Charles, et al.
Publicado: (2021)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey
por: Hunter, Theresa, et al.
Publicado: (2021)

Human Leukocyte Antigen B27‐Negative Axial Spondyloarthritis: What Do We Know?
por: Deodhar, Atul, et al.
Publicado: (2023)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
por: Braun, Jürgen, et al.
Publicado: (2021)

Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort
por: Dougados, Maxime, et al.
Publicado: (2017)

Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study
por: Kishimoto, Mitsumasa, et al.
Publicado: (2021)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9073t5eao6rat16b54h5nios7p